Mammoth Biosciences stock

Mammoth Biosciences Stock

HealthTech
Looking to sell Mammoth Biosciences Stock or Options? Get a free valuation
Founded: 2017Funding to Date: $365M
Visit website

Mammoth Biosciences has developed a detection platform based on CRISPR technology, aimed at making disease detection accessible to all. Their platform offers an efficient and cost-effective point-of-need test which can quickly detect multiple conditions simultaneously. This enables healthcare providers, researchers, and biotech professionals to leverage this innovative platform for molecular diagnostics.

Investors Include:

University of California, Decheng Capital, Tachyon Ventures, Tectonic Capital, K50 Ventures, Berkeley Frontier Fund, Plum Alley Investments, Boom Capital Ventures, Sixth Street Partners, Wireframe Ventures, Redmile Group, DHVC, Amazon.com, Mission Bay Capital, Berkeley, 8VC, Kairos HQ, Mission BioCapital, Brook Byers, Plug and Play Tech Center, Verily Life Sciences, Cardinal Ventures, Foresite Capital, Senator Investment Group, NFX.

Own Mammoth Biosciences stock or options?

Get an instant valuation

  • Completely free
  • 100% confidential & secure
  • Takes less than a minute
100% private & secure